Rutgers New Jersey Medical School will be a clinical test site for a study assessing the long term risk of chronic kidney disease in patients who recover from COVID-19. The Multi-Center Assessment of Survivors for Kidney Disease after COVID-19 (MASKeD-COVID) study – conducted by the Division of Nephrology at Mount Sinai – will assess risk in up to 4,000 patients who have recovered from COVID-19 using the artificial-intelligence diagnostic system KidneyIntelX that can incorporate novel protein biomarkers and provide insight into the disease. Researchers will also study patients’ COVID-19 antibody levels over time, which will provide insights into the interaction between immune response and kidney-related complications. Initial research findings are expected to be reported in early 2021. To read the full story.
- To Reduce Smoking Rates in Prisons, Cessation Programs Must Be Expanded and Extended.
- Rutgers Selected as Backup Center for New National 9-8-8 Mental Health Crisis Line.
- New NJACTS Publication
- Why do some people evade COVID-19 while others get reinfected?
- Rutgers Scientist Who Researches the Sense of Smell Named Rita Allen Foundation Scholar.